BofA raised the firm’s price target on Tarsus Pharmaceuticals to $60 from $55 and keeps a Buy rating on the shares after Tarsus delivered a “strong revenue beat” in the first full quarter of the Xdemvy launch. Based on Xdemvy net pricing and volume trends, the firm increased its 2024 Xdemvy revenue estimate to $105M from $76M and increased its Xdemvy ramp to $1B in expected peak sales.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TARS:
- Tarsus Pharmaceuticals reports Q4 EPS ($1.31), consensus ($1.36)
- Tarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Achievements
- Is TARS a Buy, Before Earnings?
- Tarsus Pharmaceuticals announces results from Carpo, phase 2a trial of TP-05
- Tarsus to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, February 27, 2024
